Testing dasatinib and quercetin in diabetes-related kidney disease
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether two medicines (dasatinib and quercetin) can affect “cell aging” in people with chronic kidney disease related to diabetes. You may be asked to take pills for a short period and complete follow-up visits to measure how your body responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 40 and 80 years old
- You have chronic kidney disease, with an eGFR between 15 and 45
- You have diabetes and take diabetes medicines
- Your diabetes control is not very high (A1c below 10%)
- You’re able to take pills by mouth and give informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called AZD4248 to see if it's safe for healthy people and for people with chronic kidney disease and type 2 diabetes. It also checks if a home device can accurately measure kidney function.
This study tests whether a goal-directed treatment plan using several medications can lower the risk of kidney and heart problems for people with diabetes and kidney disease. It aims to help you manage your condition more effectively.
This trial tests if a medicine called finerenone can protect kidney function in people with type 2 diabetes and early-to-moderate chronic kidney disease. It may be an option if you are already on blood pressure medication and have some protein in your urine.
This trial tests a combination of two existing drugs in people aged 55–85 with secondary progressive multiple sclerosis (SPMS). The goal is to see if the combo can slow down the disease. You need to have had SPMS for at least 12 months and not be on certain other MS treatments.
This study tests whether a generic version of the drug dasatinib works the same as the original brand-name drug. It is for healthy men only, to see how the body handles the medicine.
This study tests if matching treatments to your specific kidney disease markers can better protect your kidneys. It looks at how well Finerenone, Dapagliflozin, and Semaglutide work alone or in a sequence.
Hear when a new Chronic kidney disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.